Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719593 | 0.84 | RBP4 (0.41) | MEN1KMT2ALMNASMN1; SMN2RBP4 | |
| SCHEMBL18036690 | 0.79 | MEN1 (0.66) | MEN1KMT2A | |
| SCHEMBL6190217 | 0.79 | HTR6 (0.45) | LMNATSHR | |
| SCHEMBL30091195 | 0.79 | HTR6 (0.45) | LMNATSHR | |
| SCHEMBL23663121 | 0.79 | PDE4A (0.43) | KMT2ASMN1; SMN2TSHR | |
| SCHEMBL18036676 | 0.78 | HTR6 (0.46) | MEN1KMT2AADAM17 | |
| SCHEMBL11538060 | 0.78 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2HPGDTSHR | |
| SCHEMBL6871686 | 0.78 | RBP4 (0.48) | MEN1KMT2ALMNAADAM17SMN1; SMN2 | |
| SCHEMBL18036692 | 0.77 | HTR6 (0.60) | — | |
| SCHEMBL18036684 | 0.77 | HTR6 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083588-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-9663498-B2 | Aromatic heterocyclic compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-30 | — | — | US | disclosed |
| US-20160251339-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251339-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | MAPT, APP, PSEN1 | MEN1 1953/4885KMT2A 3082/4885LMNA 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.